文献速递脑血管病

氯吡格雷-阿司匹林对CYP2C19功能缺失等位基因非携带者且超重/肥胖患者的卒中疗效不存在

Efficacy of Clopidogrel-Aspirin Therapy for Stroke Does Not Exist in CYP2C19 Loss-of-Function Allele Noncarriers With Overweight/Obesity.
PubMed 文献 · Stroke · 2019-11-15

该研究基于2933例小卒中/短暂性脑缺血发作患者,按CYP2C19功能缺失等位基因(LoFA)携带状态和体重指数(BMI)分层,分析氯吡格雷-阿司匹林治疗对3个月卒中复发的疗效。结果显示,在LoFA非携带者且超重/肥胖(BMI≥25 kg/m2)亚组中,氯吡格雷-阿司匹林治疗未显示降低卒中复发风险(HR 0.90, 95%CI 0.60-1.36),交互作用P=0.049。结论提示BMI显著影响CYP2C19基因型与氯吡格雷-阿司匹林疗效之间的关联。

要点

  • 在LoFA非携带者且超重/肥胖患者中,氯吡格雷-阿司匹林未显示降低卒中复发风险。
  • LoFA非携带者且低/正常体重者从氯吡格雷-阿司匹林治疗中获益最明显(HR 0.40, 95%CI 0.22-0.71)。
  • BMI与CYP2C19基因型存在交互作用(P=0.049),影响氯吡格雷-阿司匹林疗效。

核心结论

  • 氯吡格雷-阿司匹林降低卒中复发风险的疗效在CYP2C19 LoFA非携带者且超重/肥胖患者中不存在。
  • BMI显著影响CYP2C19基因型与氯吡格雷-阿司匹林疗效之间的关联。

研究设计与样本

  • 基于2933例小卒中或短暂性脑缺血发作患者的分析,按CYP2C19 LoFA携带状态和BMI分层。
  • LoFA携带者定义为携带*2或*3功能缺失等位基因。
  • 低/正常体重定义为BMI<25 kg/m2,超重/肥胖定义为BMI≥25 kg/m2。
  • 主要结局为3个月时卒中复发。

主要发现

  • 共1726例(58.8%)为LoFA携带者,1275例(43.5%)为超重/肥胖(BMI≥25 kg/m2)。
  • LoFA携带者且超重/肥胖亚组中,氯吡格雷-阿司匹林治疗卒中复发的HR为0.90(95%CI 0.60-1.36)。
  • LoFA携带者且低/正常体重亚组中,HR为0.87(95%CI 0.56-1.35)。
  • LoFA非携带者且超重/肥胖亚组中,HR为0.65(95%CI 0.39-1.09)。
  • LoFA非携带者且低/正常体重亚组中,HR为0.40(95%CI 0.22-0.71),交互作用P=0.049。

临床怎么用

  • 对于CYP2C19 LoFA非携带者且超重/肥胖的小卒中/短暂性脑缺血发作患者,氯吡格雷-阿司匹林治疗可能不降低卒中复发风险。
  • 临床可考虑结合CYP2C19基因型和BMI评估氯吡格雷-阿司匹林治疗的预期获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- The role of dual-antiplatelet therapy with clopidogrel plus aspirin has been demonstrated to substantially decrease the risk of recurrent stroke among patients with minor stroke and transient ischemic attack. We aimed to determine whether the efficacy of clopidogrel-aspirin therapy among patients with minor stroke / transient ischemic attack was influenced by the stratification of CYP2C19 genotype and body mass index (BMI). Methods- CYP2C19 loss-of-function allele (LoFA) carriers were defined as patients with either LoFA of *2 or *3. Low/normal weight and overweight/obesity was defined as BMI <25 and ≥25 kg/m2, respectively. Primary outcome was defined as stroke recurrence at 3 months. Results- In a total of 2933 patients, there were 1726 (58.8%) LoFA carriers and 1275 (43.5%) patients with overweight/obesity (BMI ≥25 kg/m2). Stratified analyses by LoFA carrying status and BMI, hazard ratios (hazard ratios 95% CIs) of the clopidogrel-aspirin therapy for stroke recurrence were 0.90 (0.60-1.36), 0.87 (0.56-1.35), 0.65 (0.39-1.09), and 0.40 (0.22-0.71) among subgroups of LoFA carriers with overweight/obesity, LoFA carriers with low/normal weight, LoFA noncarriers with overweight/obesity, and LoFA noncarriers with low/normal weight, respectively, with P=0.049 for interaction. Conclusions- Efficacy of clopidogrel-aspirin therapy in reducing the risk of stroke recurrence is not present in CYP2C19 LoFA noncarriers with overweight/obesity. Our study suggests that BMI significantly influences the correlation between CYP2C19 genotype and efficacy of clopidogrel-aspirin therapy. Clinical Trial Registration- URL: https://www.clinicaltrials.gov. Unique identifier: NCT00979589.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Mo J, Chen Z, Xu J, et al. Efficacy of Clopidogrel-Aspirin Therapy for Stroke Does Not Exist in CYP2C19 Loss-of-Function Allele Noncarriers With Overweight/Obesity. Stroke. 2019. PMID: 31726963. doi:10.1161/STROKEAHA.119.026845

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。